Regeneron presents expanded Sanofi alliance worth up to $8 billion in potential payments
REGN•Regeneron’s expanded alliance with Sanofi includes $1 billion upfront, up to $7 billion in milestone payments and a 50:50 global profit split. Third-quarter 2026 revenue was $5.1 billion, while Dupixent sales rose 35% to $6.5 billion.
1. Expanded Sanofi alliance
Regeneron said its expanded alliance with Sanofi includes $1 billion upfront, up to $7 billion in milestone payments and a 50:50 global profit split. Sanofi collaboration revenue increased 68% to $2.7 billion, reflecting a full share of profits for the first time.
2. Quarterly results and trial
Third-quarter 2026 revenue totaled $5.1 billion, and non-GAAP diluted earnings were $20.07 per share. Dupixent global net sales rose 35% to $6.5 billion, with more than 1.5 million patients on therapy globally. A Phase 3 trial of fianlimab with cemiplimab missed its primary endpoint against pembrolizumab in first-line metastatic melanoma.
